Shanxi Zhendong Pharmaceutical
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sales of pharmaceutical drugs in China. It offers drugs for various fields, including tumors, dermatology, digestion, urology, and cardio-cerebral drugs. The company also provides Chinese herbal medicines. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is b… Read more
Shanxi Zhendong Pharmaceutical (300158) - Net Assets
Latest net assets as of September 2025: CN¥3.63 Billion CNY
Based on the latest financial reports, Shanxi Zhendong Pharmaceutical (300158) has net assets worth CN¥3.63 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.51 Billion) and total liabilities (CN¥882.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.63 Billion |
| % of Total Assets | 80.43% |
| Annual Growth Rate | 19.53% |
| 5-Year Change | -35.02% |
| 10-Year Change | 80.27% |
| Growth Volatility | 98.8 |
Shanxi Zhendong Pharmaceutical - Net Assets Trend (2007–2024)
This chart illustrates how Shanxi Zhendong Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanxi Zhendong Pharmaceutical (2007–2024)
The table below shows the annual net assets of Shanxi Zhendong Pharmaceutical from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.66 Billion | -28.85% |
| 2023-12-31 | CN¥5.14 Billion | -1.52% |
| 2022-12-31 | CN¥5.22 Billion | -35.15% |
| 2021-12-31 | CN¥8.05 Billion | +42.98% |
| 2020-12-31 | CN¥5.63 Billion | +3.53% |
| 2019-12-31 | CN¥5.44 Billion | +1.47% |
| 2018-12-31 | CN¥5.36 Billion | -3.51% |
| 2017-12-31 | CN¥5.56 Billion | +5.43% |
| 2016-12-31 | CN¥5.27 Billion | +159.63% |
| 2015-12-31 | CN¥2.03 Billion | +3.06% |
| 2014-12-31 | CN¥1.97 Billion | +0.60% |
| 2013-12-31 | CN¥1.96 Billion | +3.09% |
| 2012-12-31 | CN¥1.90 Billion | +2.21% |
| 2011-12-31 | CN¥1.86 Billion | +4.33% |
| 2010-12-31 | CN¥1.78 Billion | +395.77% |
| 2009-12-31 | CN¥359.31 Million | +34.72% |
| 2008-12-31 | CN¥266.72 Million | +51.18% |
| 2007-12-31 | CN¥176.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanxi Zhendong Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1671.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.01 Billion | 27.19% |
| Other Comprehensive Income | CN¥401.65 Million | 10.86% |
| Other Components | CN¥3.68 Billion | 99.49% |
| Total Equity | CN¥3.70 Billion | 100.00% |
Shanxi Zhendong Pharmaceutical Competitors by Market Cap
The table below lists competitors of Shanxi Zhendong Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Jiaxun Feihong Electrical Co Ltd
SHE:300213
|
$556.52 Million |
|
Huayi Brothers Media Corp
SHE:300027
|
$556.54 Million |
|
Banca Farmafactoring S.p.A.
LSE:0RON
|
$556.56 Million |
|
Sanhe Tongfei Refrigeration Co. Ltd.
SHE:300990
|
$556.64 Million |
|
SÜSS MicroTec SE
PINK:SESMF
|
$556.12 Million |
|
PT Indo Tambangraya Megah Tbk
F:3IB
|
$555.98 Million |
|
Sunway Co Ltd
SHG:603333
|
$555.88 Million |
|
Kura Oncology Inc
NASDAQ:KURA
|
$555.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanxi Zhendong Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,178,856,723 to 3,697,629,286, a change of -1,481,227,437 (-28.6%).
- Net loss of 1,328,563,928 reduced equity.
- Dividend payments of 584,652 reduced retained earnings.
- Share repurchases of 105,593,895 reduced equity.
- Other comprehensive income increased equity by 401,653,355.
- Other factors decreased equity by 448,138,317.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-1.33 Billion | -35.93% |
| Dividends Paid | CN¥584.65K | -0.02% |
| Share Repurchases | CN¥105.59 Million | -2.86% |
| Other Comprehensive Income | CN¥401.65 Million | +10.86% |
| Other Changes | CN¥-448.14 Million | -12.12% |
| Total Change | CN¥- | -28.60% |
Book Value vs Market Value Analysis
This analysis compares Shanxi Zhendong Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.54x to 1.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.52 | CN¥5.97 | x |
| 2008-12-31 | CN¥0.75 | CN¥5.97 | x |
| 2009-12-31 | CN¥0.86 | CN¥5.97 | x |
| 2010-12-31 | CN¥4.05 | CN¥5.97 | x |
| 2011-12-31 | CN¥3.21 | CN¥5.97 | x |
| 2012-12-31 | CN¥3.29 | CN¥5.97 | x |
| 2013-12-31 | CN¥3.38 | CN¥5.97 | x |
| 2014-12-31 | CN¥3.40 | CN¥5.97 | x |
| 2015-12-31 | CN¥3.46 | CN¥5.97 | x |
| 2016-12-31 | CN¥7.18 | CN¥5.97 | x |
| 2017-12-31 | CN¥10.72 | CN¥5.97 | x |
| 2018-12-31 | CN¥5.17 | CN¥5.97 | x |
| 2019-12-31 | CN¥5.29 | CN¥5.97 | x |
| 2020-12-31 | CN¥5.49 | CN¥5.97 | x |
| 2021-12-31 | CN¥7.86 | CN¥5.97 | x |
| 2022-12-31 | CN¥5.11 | CN¥5.97 | x |
| 2023-12-31 | CN¥5.04 | CN¥5.97 | x |
| 2024-12-31 | CN¥3.61 | CN¥5.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanxi Zhendong Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.72%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 1.35x
- Recent ROE (-35.93%) is below the historical average (5.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 22.24% | 12.44% | 0.68x | 2.65x | CN¥21.59 Million |
| 2008 | 22.27% | 12.88% | 0.93x | 1.86x | CN¥32.71 Million |
| 2009 | 18.95% | 12.87% | 0.82x | 1.79x | CN¥32.13 Million |
| 2010 | 5.24% | 9.90% | 0.43x | 1.24x | CN¥-83.52 Million |
| 2011 | 6.54% | 9.35% | 0.57x | 1.23x | CN¥-63.46 Million |
| 2012 | 4.86% | 6.60% | 0.54x | 1.37x | CN¥-96.58 Million |
| 2013 | 3.80% | 4.46% | 0.59x | 1.44x | CN¥-120.58 Million |
| 2014 | 2.14% | 2.19% | 0.67x | 1.46x | CN¥-153.95 Million |
| 2015 | 3.24% | 2.86% | 0.56x | 2.04x | CN¥-134.85 Million |
| 2016 | 3.87% | 6.19% | 0.48x | 1.31x | CN¥-321.55 Million |
| 2017 | 5.44% | 8.08% | 0.49x | 1.37x | CN¥-252.59 Million |
| 2018 | -2.75% | -4.31% | 0.47x | 1.35x | CN¥-683.12 Million |
| 2019 | 2.63% | 3.25% | 0.64x | 1.27x | CN¥-400.85 Million |
| 2020 | 4.64% | 5.41% | 0.64x | 1.35x | CN¥-302.46 Million |
| 2021 | 32.40% | 51.38% | 0.50x | 1.25x | CN¥1.81 Billion |
| 2022 | -0.98% | -1.38% | 0.57x | 1.25x | CN¥-576.71 Million |
| 2023 | -0.85% | -1.21% | 0.59x | 1.19x | CN¥-561.87 Million |
| 2024 | -35.93% | -44.72% | 0.60x | 1.35x | CN¥-1.70 Billion |
Industry Comparison
This section compares Shanxi Zhendong Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanxi Zhendong Pharmaceutical (300158) | CN¥3.63 Billion | 22.24% | 0.24x | $556.46 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |